Design, synthesis, and SAR study of a series of N-alkyl-N′-[2- (aryloxy)-5-nitrobenzenesulfonyl]ureas and -cyanoguanidine as selective antagonists of the TPα and TPβ isoforms of the human thromboxane A2 receptor

Journal of Medicinal Chemistry

Volumn 50, Issue 16, 2007, Pages 3928-3936

  Hanson, Julien ^a   Dogné, Jean Michel ^a,c   Ghiotto, Jérémie ^a   Moray, Anne Lise ^a   Kinsella, B Therese ^b   Pirotte, Bernard ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF NAMUR   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ALKYL GROUP; CALCIUM; G PROTEIN COUPLED RECEPTOR; GUANIDINE DERIVATIVE; N PENTYL N' [2 (4 ETHOXYPHENOXY) 5 NITROBENZENESULFONYL]UREA; N TERT BUTYL N' [2 (3 METHOXYPHENOXY) 5 NITROBENZENESULFONYL]UREA; N TERT BUTYL N' [2 (3 METHYLPHENOXY) 5 NITROBENZENESULFONYL]UREA; NITRILE; NITROBENZENE DERIVATIVE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; SULFONE DERIVATIVE; THROMBOXANE A2 RECEPTOR; THROMBOXANE A2 RECEPTOR ALPHA; THROMBOXANE A2 RECEPTOR BETA; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; DRUG DESIGN; DRUG DETERMINATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; NORMAL HUMAN; PROTEIN FAMILY; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION;

ADULT; CALCIUM; CELL LINE; DRUG DESIGN; FEMALE; GUANIDINES; HUMANS; MALE; NITRILES; NITROBENZENES; PLATELET AGGREGATION INHIBITORS; PROTEIN ISOFORMS; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONYLUREA COMPOUNDS;

EID: 34548070853     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070427h     Document Type: Article

References (18)

1. Hamberg, M.; Svensson, J.; Samuelsson, B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl Acad. Sci. U.S.A. 1975, 72, 2994-2998.
2. Moncada, S.; Ferreira, S. H.; Vane, J. R. Bioassay of prostaglandins and biologically active substances derived from arachidonic acid. Adv Prostaglandin Thromboxane Res. 1978, 5, 211-236.
3. Dogne, J. M.; de Leval, X.; Hanson, J.; Frederich, M.; Lambermont, B., et al. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr. Med. Chem. 2004, 11, 1223-1241.
4. Coleman, R. A.; Smith, W. L.; Narumiya, S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 1994, 46, 205-229.
5. Hirata, M.; Hayashi, Y.; Ushikubi, F.; Yokota, Y.; Kageyama, R., et al. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 1991, 349, 617-620.
6. Raychowdhury, M. K.; Yukawa, M.; Collins, L. J.; McGrail, S. H.; Kent, K. C., et al. Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J. Biol. Chem. 1994, 269, 19256-19261.
7. Reid, H. M.; Kinsella, B. T. The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for nitric oxide-mediated desensitization. Independent modulation of Tp alpha signaling by nitric oxide and prostacyclin. J. Biol. Chem. 2003, 278, 51190-51202.
8. Walsh, M. T.; Foley, J. F.; Kinsella, B. T. The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for prostacyclin-mediated desensitization. J. Biol. Chem. 2000, 275, 20412-20423.
9. Kinsella, B. T. Thromboxane A2 signalling in humans: a 'Tail' of two receptors. Biochem. Soc. Trans. 2001, 29, 641-654.
10. Ashton, A. W.; Ware, J. A. Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ. Res. 2004, 95, 372-379.
11. Habib, A.; FitzGerald, G. A.; Maclouf, J. Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. J. Biol. Chem. 1999, 274, 2645-2651.
12. Halushka, P. V. Thromboxane A(2) receptors: where have you gone? Prostaglandins Other Lipid Mediat. 2000, 60, 175-189.
13. Hanson, J.; Reynaud, D.; Qiao, N.; Devel, P.; Moray, A. L., et al. Synthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta isoforms of the human thromboxane receptor. J. Med. Chem. 2006, 49, 3701-3709.
14. Dogne, J. M.; Hanson, J.; de Leval, X.; Kolh, P.; Tchana-Sato, V., et al. Pharmacological characterization of N-tert-butyl-N′-[2- (4′-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time. J. Pharmacol. Exp. Ther. 2004, 309, 498-505.
15. Meerwein, H.; Dittmar, G.; Gollner, R.; Hafner, K.; Mensch, F., et al. Aromatic diazo compounds. II. Preparation of aromatic sulfonyl chlorides, a new modification of the Sandmeyer reaction. Chem. Ber. 1957, 90, 841-852.
16. Dogne, J. M.; Wouters, J.; Rolin, S.; Michaux, C.; Pochet, L., et al. Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor. J. Pharm. Pharmacol. 2001, 53, 669-680.
17. Lin, K.; Sadee, W.; Quillan, J. M. Rapid measurements of intracellular calcium using a fluorescence plate reader. Biotechniques 1999, 26, 318-322, 324-316.
18. Born, G. V.; Cross, M. J. The Aggregation of Blood Platelets. J. Physiol. 1963, 168, 178-195.